drug category, as high ErbB2 expression in those cancer cell lines was found to be significantly associated with resistance to 40% of the drugs targeting protein stability and degradation, followed by breast cancer in which 30% of the drugs targeting Protein stab. Here, ERBB2 is linked to breast carcinoma.